accredited facility that plays a vital role in advancing clinical research at Memorial Sloan Kettering (MSK). The mission of the Core is to develop, validate, and support the implementation of phase I ...

Fintel reports that on March 12, 2025, Citigroup upgraded their outlook for Core Laboratories (NYSE:CLB) from Sell to Neutral. As of March 4, 2025, the average one-year price target for Core ...

It has been about a month since the last earnings report for Core Laboratories (CLB). Shares have lost about 16% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Core Laboratories (NYSE:CLB) +4.6% in Wednesday's trading as Citi upgrades the provider of core and fluid analysis in the petroleum industry to Neutral from Sell with a $16 price target ...